[go: up one dir, main page]

DK2448637T3 - Anvendelse af ét fytocannabinoid eller en kombination af fytocannabinoider til behandling af epilepsi - Google Patents

Anvendelse af ét fytocannabinoid eller en kombination af fytocannabinoider til behandling af epilepsi

Info

Publication number
DK2448637T3
DK2448637T3 DK10734541.5T DK10734541T DK2448637T3 DK 2448637 T3 DK2448637 T3 DK 2448637T3 DK 10734541 T DK10734541 T DK 10734541T DK 2448637 T3 DK2448637 T3 DK 2448637T3
Authority
DK
Denmark
Prior art keywords
phytocannabinoid
phytocannabinoids
epilepsy
treatment
combination
Prior art date
Application number
DK10734541.5T
Other languages
English (en)
Other versions
DK2448637T4 (da
Inventor
Tetsuro Kikuchi
Ben Whalley
Gary Stephens
Claire Williams
Geoffrey Guy
Stephen Wright
Original Assignee
Gw Pharma Ltd
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41008705&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2448637(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gw Pharma Ltd, Otsuka Pharma Co Ltd filed Critical Gw Pharma Ltd
Application granted granted Critical
Publication of DK2448637T3 publication Critical patent/DK2448637T3/da
Publication of DK2448637T4 publication Critical patent/DK2448637T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
DK10734541.5T 2009-07-03 2010-06-29 Anvendelse af et phytocannabinoid eller en kombination af phytocannabinoider i behandling af epilepsi DK2448637T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0911580A GB2471523A (en) 2009-07-03 2009-07-03 Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
PCT/GB2010/051066 WO2011001169A1 (en) 2009-07-03 2010-06-29 Use of one or a combination of phyto-cannabinoids in the treatment of epilepsy

Publications (2)

Publication Number Publication Date
DK2448637T3 true DK2448637T3 (da) 2014-05-26
DK2448637T4 DK2448637T4 (da) 2022-09-12

Family

ID=41008705

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10734541.5T DK2448637T4 (da) 2009-07-03 2010-06-29 Anvendelse af et phytocannabinoid eller en kombination af phytocannabinoider i behandling af epilepsi

Country Status (28)

Country Link
US (4) US9066920B2 (da)
EP (3) EP3718603A1 (da)
JP (2) JP5904938B2 (da)
KR (1) KR101727000B1 (da)
CN (2) CN106236744A (da)
AR (1) AR077448A1 (da)
AU (1) AU2010267775C1 (da)
BR (1) BR112012000076A2 (da)
CA (2) CA2766082C (da)
CY (1) CY1115338T1 (da)
DK (1) DK2448637T4 (da)
ES (1) ES2460623T5 (da)
GB (3) GB2471523A (da)
HR (1) HRP20140398T4 (da)
IL (1) IL217280B (da)
IN (1) IN2012DN00804A (da)
MX (1) MX2012000257A (da)
MY (1) MY156759A (da)
NZ (2) NZ620838A (da)
PL (1) PL2448637T5 (da)
PT (1) PT2448637E (da)
RU (1) RU2563143C2 (da)
SG (1) SG176914A1 (da)
SI (1) SI2448637T2 (da)
TW (1) TWI461191B (da)
UA (1) UA108852C2 (da)
WO (1) WO2011001169A1 (da)
ZA (1) ZA201200373B (da)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2377218A (en) * 2001-05-04 2003-01-08 Gw Pharmaceuticals Ltd Process and apparatus for extraction of active substances and enriched extracts from natural products
US9168278B2 (en) * 2004-11-16 2015-10-27 Gw Pharma Limited Use for cannabinoid
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
US11062795B2 (en) 2007-03-02 2021-07-13 Enigami Systems, Inc. Healthcare data system
GB2471523A (en) 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
TWI583374B (zh) * 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
GB2479153B (en) * 2010-03-30 2014-03-19 Gw Pharma Ltd The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy
GB2487712B (en) * 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2514054A (en) * 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US12544389B2 (en) 2014-05-29 2026-02-10 Fresh Cut Development, Llc Stable cannabinoid formulations
US11911361B2 (en) 2014-05-29 2024-02-27 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US10319475B1 (en) 2014-06-13 2019-06-11 Enigami Systems, Inc. Method and apparatus for determining relationships between medications and symptoms
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
CA2961410C (en) 2014-09-16 2023-07-11 India Globalization Capital, Inc. Cannabinoid composition and method for treating pain
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
CA2974895A1 (en) 2015-01-25 2016-07-28 India Globalization Capital, Inc. Composition and method for treating seizure disorders
US10238745B2 (en) 2015-01-31 2019-03-26 Constance Therapeutics, Inc. Cannabinoid composition and products including α-tocopherol
CA2974292C (en) 2015-01-31 2024-04-16 Constance Therapeutics, Inc. Methods for preparation of cannabis oil extracts and compositions
CA2981285A1 (en) * 2015-04-01 2016-10-06 India Globalization Capital, Inc. Composition and method for treating seizure disorders
AU2016255707A1 (en) * 2015-04-28 2017-11-30 The Regents Of The University Of California Uses of cannabidiol for treatment of infantile spasms
GB2539472A (en) * 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
GB2541191A (en) * 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
WO2017027651A1 (en) 2015-08-12 2017-02-16 India Globalization Capital, Inc. Method and composition for treating cachexia and eating disorders
CA3006182A1 (en) 2015-11-24 2017-06-01 Constance Therapeutics, Inc. Cannabis oil compositions and methods for preparation thereof
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
EP3471746A4 (en) 2016-06-15 2020-02-26 India Globalization Capital, Inc. METHOD AND COMPOSITION FOR TREATING CRAMPING SEASONS
EP3478307A4 (en) 2016-06-29 2020-02-26 Cannscience Innovations Inc. DECARBOXYLATED CANNABIS RESINS, USES THEREOF AND METHOD FOR THE PRODUCTION THEREOF
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
CN108236608B (zh) * 2016-12-27 2020-05-08 汉义生物科技（北京）有限公司 大麻二酚与氨己烯酸的药物组合物及其用途
CN108245510B (zh) * 2016-12-29 2020-11-20 汉义生物科技（北京）有限公司 大麻二酚与乙丙酰脲类抗癫痫药物的组合物及其用途
CN108245517B (zh) * 2016-12-29 2020-05-08 汉义生物科技（北京）有限公司 大麻二酚与拉莫三嗪的药物组合物及其用途
CN108245499B (zh) * 2016-12-29 2020-11-20 汉义生物科技（北京）有限公司 大麻二酚与双链脂肪酸类抗癫痫药物的组合物及其用途
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
CN108785298A (zh) * 2017-04-27 2018-11-13 汉义生物科技（北京）有限公司 一种用于治疗癫痫的药物组合物、其制备方法及用途
US20180352848A1 (en) * 2017-06-07 2018-12-13 NC3 Systems Smokable cannabis-based product with reduced psychoactive effects
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
GB2583526A (en) 2019-05-03 2020-11-04 Gw Res Ltd Use of cannabidiol in the treatment of tuberous sclerosis complex
CN110101804A (zh) * 2019-05-30 2019-08-09 厦门梓素生物科技有限公司 一种含大麻二酚提取物的癫痫药物组合及其制备方法
CN114423416A (zh) * 2019-09-17 2022-04-29 Zyne制药公司 Syngap1脑病的治疗
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
EP3912485A1 (en) 2020-05-18 2021-11-24 Del-Vis Sp. z o.o. Cigarette product and a method for manufacturing the product
GB2597279A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
WO2022017936A1 (en) * 2020-07-20 2022-01-27 GW Research Limited Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
EP4188090A4 (en) 2020-07-28 2024-08-14 Impello Biosciences, Inc. METHODS AND COMPOSITIONS FOR MODIFYING SECONDARY METABOLITES IN PLANTS
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
GB2604132A (en) 2021-02-25 2022-08-31 Gw Res Ltd Use of cannabidiol and clobazam in the treatment of childhood-onset epilepsy syndromes
US11337934B1 (en) 2021-04-08 2022-05-24 Lanny Leo Johnson Compositions including a cannabinoid and protocatechuic acid
US20250108064A1 (en) 2021-07-29 2025-04-03 Emory University Phosphate prodrugs of cannabinoids
JP2025512495A (ja) * 2022-04-12 2025-04-17 シャッケルフォード・ファーマ・インコーポレーテッド 発作性障害の治療

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949582B1 (en) 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
DE10051427C1 (de) * 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
CZ306277B6 (cs) * 2001-02-14 2016-11-09 Gw Pharma Limited Pumpičkou aktivovaná kapalná sprejová formulace
GB2381450B (en) * 2001-10-31 2006-05-31 Gw Pharma Ltd Compositions for administration of natural or synthetic cannabinoids by vaporisation
GB0202385D0 (en) 2002-02-01 2002-03-20 Gw Pharma Ltd Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions
ITPD20020138A1 (it) 2002-05-24 2003-11-24 Matteo Bevilacqua Composizione di sostanze a base terpenica, metodo di preparazione e metodo di dispersione in ambiente della medesima.
DE10226494A1 (de) 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
EP1542657B8 (en) * 2002-08-14 2012-03-14 GW Pharma Limited Cannabinoid liquid formulations for mucosal amdinistration
PL226646B1 (pl) 2002-08-14 2017-08-31 Gw Pharma Ltd Botaniczna substancja lekowa
US9168278B2 (en) 2004-11-16 2015-10-27 Gw Pharma Limited Use for cannabinoid
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
GB2434312B (en) 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
US9877928B2 (en) 2006-05-30 2018-01-30 Air Systems, Inc. Gear drive damper
GB2438682A (en) 2006-06-01 2007-12-05 Gw Pharma Ltd New use for cannabinoids
GB2439393B (en) * 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
GB2449691A (en) 2007-05-31 2008-12-03 Gw Pharma Ltd A reference plant lacking medicinal active compound expression
GB2450753B (en) * 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
GB2459637B (en) 2008-01-21 2012-06-06 Gw Pharma Ltd New use for cannabinoids
DK2280687T3 (da) 2008-03-26 2019-05-27 Stichting Sanammad Tyggegummisammensætninger omfattende cannabinoider
GB2478074B (en) 2008-06-04 2012-12-26 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2478072B (en) 2008-06-04 2012-12-26 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2471523A (en) 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
GB2479153B (en) 2010-03-30 2014-03-19 Gw Pharma Ltd The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB201111261D0 (en) 2011-07-01 2011-08-17 Gw Pharma Ltd Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders
EP2747770A1 (en) 2011-08-26 2014-07-02 BIAL - Portela & Cª S.A. Treatments involving eslicarbazepine acetate or eslicarbazepine
GB2514054A (en) 2011-09-29 2014-11-12 Gw Pharma Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2496687A (en) 2011-11-21 2013-05-22 Gw Pharma Ltd Tetrahydrocannabivarin (THCV) in the protection of pancreatic islet cells
US20150181924A1 (en) 2013-10-31 2015-07-02 Michael R. Llamas Cannabidiol liquid composition for smoking
WO2015142501A1 (en) 2014-03-21 2015-09-24 Bodybio Inc. Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids
JP6659933B2 (ja) 2014-05-29 2020-03-04 フレッシュ・カット・ディベロップメント・エル・エル・シー 安定なカンナビノイド製剤
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy

Also Published As

Publication number Publication date
AU2010267775B2 (en) 2016-10-06
AU2010267775A1 (en) 2012-02-23
UA108852C2 (ru) 2015-06-25
IN2012DN00804A (da) 2015-06-26
KR20120088648A (ko) 2012-08-08
US9066920B2 (en) 2015-06-30
RU2012103603A (ru) 2013-08-10
MY156759A (en) 2016-03-31
NZ620838A (en) 2015-08-28
US20150335590A1 (en) 2015-11-26
ES2460623T5 (es) 2022-10-14
GB2471565B (en) 2012-07-04
KR101727000B1 (ko) 2017-05-02
PL2448637T5 (pl) 2022-10-03
SI2448637T1 (sl) 2014-07-31
JP2012532093A (ja) 2012-12-13
MX2012000257A (es) 2012-01-27
CA2766082A1 (en) 2011-01-06
GB2471565A (en) 2011-01-05
PT2448637E (pt) 2014-05-27
WO2011001169A1 (en) 2011-01-06
AR077448A1 (es) 2011-08-31
CA3040410A1 (en) 2011-01-06
IL217280B (en) 2018-05-31
TW201105318A (en) 2011-02-16
TWI461191B (zh) 2014-11-21
RU2563143C2 (ru) 2015-09-20
AU2010267775C1 (en) 2020-02-27
US20190247324A1 (en) 2019-08-15
CN102596322A (zh) 2012-07-18
IL217280A0 (en) 2012-02-29
CA3040410C (en) 2023-03-28
HK1164766A1 (en) 2012-09-28
EP2727626A1 (en) 2014-05-07
PL2448637T3 (pl) 2014-08-29
CY1115338T1 (el) 2017-01-04
JP2016166205A (ja) 2016-09-15
US9522123B2 (en) 2016-12-20
GB2471523A (en) 2011-01-05
HRP20140398T1 (hr) 2014-06-20
CA2766082C (en) 2019-06-11
CN106236744A (zh) 2016-12-21
GB2485291A (en) 2012-05-09
DK2448637T4 (da) 2022-09-12
US20120165402A1 (en) 2012-06-28
GB201010897D0 (en) 2010-08-11
GB2485291B (en) 2013-03-27
BR112012000076A2 (pt) 2020-06-02
ES2460623T3 (es) 2014-05-14
EP3718603A1 (en) 2020-10-07
GB201121919D0 (en) 2012-02-01
HRP20140398T4 (hr) 2022-10-14
EP2448637B1 (en) 2014-03-12
SG176914A1 (en) 2012-01-30
NZ597704A (en) 2014-05-30
JP5904938B2 (ja) 2016-04-20
SI2448637T2 (sl) 2022-10-28
US20170273913A1 (en) 2017-09-28
EP2448637B2 (en) 2022-06-08
GB0911580D0 (en) 2009-08-12
EP2448637A1 (en) 2012-05-09
ZA201200373B (en) 2012-09-26

Similar Documents

Publication Publication Date Title
DK2448637T3 (da) Anvendelse af ét fytocannabinoid eller en kombination af fytocannabinoider til behandling af epilepsi
DK2498771T3 (da) Anvendelse af bethanechol til behandling af xerostomi
DK2451796T3 (da) Tofaanaloger til behandling af dermatologiske lidelser eller tilstande
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
DK2935303T3 (da) 4`-fluornukleosider, 4`-fluornukleotider og analoger dertil til behandling af HCV
DK2451482T3 (da) Kombinationsterapi til behandlingen af diabetes
DK3192520T3 (da) Terapeutiske midler til reducering af niveauerne af parathyreoideahormon
EP2671451A4 (en) VIRENINAKTIVATOR
DK2459553T3 (da) Furazanobenzimidazoler som prodrug til behandling af neoplastiske eller autoimmune sygdomme
DK2635282T3 (da) Sammensætninger til behandling af myelofibrose
DK2349310T3 (da) Polypeptid til behandling eller forebyggelse af adhæsioner
DK2117525T3 (da) Anvendelse af 1-phenyl-3-dimethylamino-propanforbindelser til behandling af neuropatismerte
DK2164572T3 (da) Carbamoyl-cyclohexaner til behandling af akut mani
DK2702992T3 (da) Anvendelse af melatonin til behandling af og/eller forebyggelse af mucositis
DK2462108T3 (da) Fremgangsmåde til fremstilling af pyrazolcarboxylsyreamider
DK2516359T3 (da) Fremgangsmåde til fremstilling af ethylbenzen
DK3311810T3 (da) Anvendelse af sulcardin til behandling af atrieflimmer
HRP20160577T1 (hr) Liječenje osteoartritisa
DK2285416T3 (da) Konjugat til behandlingen af mesotheliom
DK2455064T3 (da) Indretning til behandling af periodontal sygdom
DK2323686T3 (da) Adiponectin til behandling af lungesygdom
DK3388111T3 (da) Organoarsenforbindelse til behandlingen af kræft
DK2310017T3 (da) Nifurtimox til behandling af sygdomme fremkaldt af trichomonadida
DK2361627T3 (da) Sammensætning til forebyggelse eller behandling af øjensygdomme